Is Aurobindo Pharma the Best Stock in Its Sector? A Look at the Numbers

Is Aurobindo Pharma the best stock in its sector? The stock trades on the NSE at Rs 1,678 as of 16 October 2026, within its 52-week range of Rs 1,080.10 to Rs 1,740.00. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Aurobindo Pharma

Aurobindo Pharma Ltd is a Hyderabad based drug maker with a global footprint in generic medicines. Its business includes oral and injectable formulations, active pharmaceutical ingredients and a growing biosimilars effort, with the United States and Europe as major markets. At a market capitalisation of Rs 96,376 Cr, it is tracked as part of the Pharmaceuticals sector on Univest.

Is Aurobindo Pharma the Best Stock in Its Sector?

Aurobindo Pharma makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, backed by its return on equity. Aurobindo Pharma's 25.97x P/E is below the 36.42x Industry P/E, though above Lupin at 16.14x and Zydus Lifesciences at 24.78x, while its 9.25% ROE is lower than Lupin at 23.76% and Zydus Lifesciences at 18.59%, and its debt to equity ratio of 0.21 is below Lupin at 0.29 and Zydus Lifesciences at 0.46.

Metric	Aurobindo Pharma
CMP (NSE)	Rs 1,677.90
52-Week High / Low	Rs 1,740.00 / Rs 1,080.10
Market Cap	Rs 96,376 Cr
P/E (TTM) vs Industry P/E	25.97x vs 36.42x
P/B	2.54
ROE	9.25%
EPS (TTM)	Rs 64.49
Dividend Yield	0.24%
Debt to Equity	0.21

Compare Aurobindo Pharma Against Other Pharmaceuticals Sector Stocks

How Aurobindo Pharma Compares Against Its Pharmaceuticals Sector Peers

The table below sets Aurobindo Pharma against 2 other Pharmaceuticals sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Aurobindo Pharma	96,376	25.97	9.25%	0.21
Lupin	89,592	16.14	23.76%	0.29
Zydus Lifesciences	1,13,790	24.78	18.59%	0.46
Peer average (2 companies)	-	20.46	21.18%	0.38

Measured against the peer averages, Aurobindo Pharma's P/E is 27 percent above the 20.46x average, and its ROE is 11.93 percentage points below the 21.18% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.

What Makes Aurobindo Pharma Worth Watching in Pharmaceuticals

• Scale: At Rs 96,376 Cr, its market capitalisation is larger than Lupin (Rs 89,592 Cr), though smaller than Zydus Lifesciences (Rs 1,13,790 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
• Sector drivers: Launches of new generics and injectables, steady demand in regulated markets and progress in biosimilars influence its growth.
• Key risk: Price erosion in US generics and regulatory inspections at plants can weigh on margins, and its return on equity trails several large peers.

Aurobindo Pharma Valuation: Is It Justified?

At a P/B ratio of 2.54, the market pays about Rs 2.54 for every rupee of book value, and the EPS (TTM) of Rs 64.49 is the earnings base behind the P/E. The stock trades about 4 percent below its 52-week high and about 55 percent above its 52-week low. The dividend yield of 0.24% is a modest income component, so returns depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Aurobindo Pharma and other Pharmaceuticals sector stocks.

How to Track Aurobindo Pharma Before You Invest

Before deciding whether Aurobindo Pharma deserves its label as the best stock in its sector for your own portfolio, compare it directly against Pharmaceuticals sector peers using the steps below.

1. Open the Univest Screener and search for Aurobindo Pharma to view live price, valuation ratios, and peer comparisons within the Pharmaceuticals sector.
2. Compare its P/E, P/B, and ROE against other Pharmaceuticals sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Aurobindo Pharma gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Pharmaceuticals depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Aurobindo Pharma the best stock in its sector?

Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Aurobindo Pharma has a 9.25% ROE and trades at 25.97x P/E against a 36.42x Industry P/E. Against the 2 peers compared in this article, its ROE is below the 21.18% peer average and its P/E is above the 20.46x peer average. Its debt to equity ratio of 0.21 is below the 0.38 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.

What is the current share price of Aurobindo Pharma?

Ans. Aurobindo Pharma was trading at Rs 1,677.90 on the NSE as of 16 October 2026, and its 52-week range runs from Rs 1,080.10 to Rs 1,740.00. That leaves the share price 4 percent short of the 52-week high and 55 percent clear of the 52-week low. Its market capitalisation is Rs 96,376 Cr and its EPS (TTM) is Rs 64.49, which is the earnings figure behind the 25.97x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.

What sector does Aurobindo Pharma belong to?

Ans. Aurobindo Pharma is classified under the Pharmaceuticals sector on Univest, and that group of listed companies is the reference point for the 36.42x Industry P/E used in this article. The 2 named peers compared here are Lupin and Zydus Lifesciences, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Pharmaceuticals sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.

How does Aurobindo Pharma compare to its sector peers on P/E?

Ans. Aurobindo Pharma's P/E of 25.97x is above the 20.46x average of the 2 named peers, with Lupin at 16.14x and Zydus Lifesciences at 24.78x. It also sits below the 36.42x Industry P/E, which is the benchmark for the wider Pharmaceuticals sector. A P/E that is above a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 2.54 gives one more view of how the market values its book value.

What is Aurobindo Pharma's return on equity?

Ans. Aurobindo Pharma reported a return on equity of 9.25%, which is below the 21.18% average of its named peers, with Lupin at 23.76% and Zydus Lifesciences at 18.59%. ROE shows how much profit a company generates on every rupee of shareholders' equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.21 against a peer average of 0.38. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.

Should I invest in Aurobindo Pharma based on its sector position?

Ans. Sector position is only one input into an investment decision. Aurobindo Pharma has a 9.25% ROE and a 25.97x P/E, which make it worth researching further, and its dividend yield is 0.24%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.